CN116472053A - Crf2受体激动剂及其在治疗中的用途 - Google Patents

Crf2受体激动剂及其在治疗中的用途 Download PDF

Info

Publication number
CN116472053A
CN116472053A CN202180066716.XA CN202180066716A CN116472053A CN 116472053 A CN116472053 A CN 116472053A CN 202180066716 A CN202180066716 A CN 202180066716A CN 116472053 A CN116472053 A CN 116472053A
Authority
CN
China
Prior art keywords
lys
gln
gglu
lysine
glutamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180066716.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·伊里亚诺
L·卢卡特斯
L·莱德因
P·鲍维格
P·扎尼科
M-L·奥责奥克斯
N·哈兰德
Z·李
R·埃尔沃特
A·艾维斯
E·比安基
A·桑托普雷特
D·罗沃思
M·特利佩皮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CN116472053A publication Critical patent/CN116472053A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180066716.XA 2020-08-19 2021-08-18 Crf2受体激动剂及其在治疗中的用途 Pending CN116472053A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20315387.9 2020-08-19
EP20315387 2020-08-19
PCT/EP2021/072923 WO2022038179A1 (en) 2020-08-19 2021-08-18 Crf2 receptor agonists and their use in therapy

Publications (1)

Publication Number Publication Date
CN116472053A true CN116472053A (zh) 2023-07-21

Family

ID=72615799

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180066716.XA Pending CN116472053A (zh) 2020-08-19 2021-08-18 Crf2受体激动剂及其在治疗中的用途

Country Status (16)

Country Link
US (1) US20250243255A1 (enExample)
EP (2) EP4199946B1 (enExample)
JP (1) JP7832927B2 (enExample)
KR (1) KR20230051583A (enExample)
CN (1) CN116472053A (enExample)
AU (1) AU2021328673A1 (enExample)
CA (1) CA3192032A1 (enExample)
ES (1) ES2988026T3 (enExample)
HR (1) HRP20240906T1 (enExample)
HU (1) HUE066991T2 (enExample)
IL (1) IL300464A (enExample)
IS (1) IS3063B (enExample)
MX (1) MX2023002087A (enExample)
PL (1) PL4199946T3 (enExample)
WO (1) WO2022038179A1 (enExample)
ZA (1) ZA202301784B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
EP4234574A1 (en) * 2022-02-23 2023-08-30 Corteria Pharmaceuticals Crf2 receptor agonists and their use in therapy
WO2025104264A1 (en) 2023-11-17 2025-05-22 Gubra A/S Hcrhr2 selective polypeptides
TW202544027A (zh) * 2024-04-19 2025-11-16 美商紐羅克里生物科學有限公司 促皮質素釋放因子受體２（ｃｒｆｒ２）促效劑
WO2025230248A1 (ko) * 2024-04-30 2025-11-06 한미약품 주식회사 Crf2 수용체 작용제와 그 아실화 결합체의 용도
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CN104356224A (zh) 2014-10-24 2015-02-18 杭州阿德莱诺泰制药技术有限公司 一种制备萨摩鲁泰的方法
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy

Also Published As

Publication number Publication date
KR20230051583A (ko) 2023-04-18
HRP20240906T1 (hr) 2024-10-11
EP4199946A1 (en) 2023-06-28
ZA202301784B (en) 2024-01-31
EP4435001A3 (en) 2024-10-09
WO2022038179A1 (en) 2022-02-24
PL4199946T3 (pl) 2024-08-19
IL300464A (en) 2023-04-01
HUE066991T2 (hu) 2024-09-28
MX2023002087A (es) 2023-03-23
AU2021328673A1 (en) 2023-03-30
JP2023541798A (ja) 2023-10-04
JP7832927B2 (ja) 2026-03-18
EP4199946C0 (en) 2024-06-05
IS3063B (is) 2025-06-15
US20250243255A1 (en) 2025-07-31
EP4435001A2 (en) 2024-09-25
ES2988026T3 (es) 2024-11-19
CA3192032A1 (en) 2022-02-24
EP4199946B1 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
CN116472053A (zh) Crf2受体激动剂及其在治疗中的用途
JP6228187B2 (ja) Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
CN1823088B (zh) 结合红细胞生成素受体的新肽
CN111491658A (zh) 肠促胰岛素类似物及其用途
JP2022527803A (ja) マルチ受容体刺激剤及びその医療上の使用
CN102532301B (zh) 一类新型的Exendin-4类似物及其制备方法
TW201716431A (zh) 升糖素及ｇｌｐ－１共激動劑化合物
KR20160079875A (ko) Ｇｉｐ-ｇｌｐ-1 이원 효능제 화합물 및 방법
KR102886870B1 (ko) 이중 수용체 아고니즘 작용을 갖는 폴리펩티드 유도체 및 그 용도
CN114787183A (zh) 肠促胰岛素类似物及其用途
CN101389648A (zh) 肽胃泌酸调节素衍生物
CN104031140A (zh) 糖依赖性胰岛素释放肽的截短类似物
KR20200116085A (ko) 변형된 지질화된 릴랙신 b 사슬 펩타이드 및 이들의 치료적 용도
EP4482578B1 (en) Crf2 receptor agonists and their use in therapy
JP2022507239A (ja) グルカゴン由来ペプチド及びその用途
RU2845766C1 (ru) Агонисты рецептора crf2 и их применение в терапии
JP2026071260A (ja) Ｃｒｆ２受容体アゴニスト及び治療におけるその使用
JP2005082489A (ja) 新規な摂食促進ペプチド、新規な成長ホルモン分泌促進ペプチド
JP2005082489A6 (ja) 新規な摂食促進ペプチド、新規な成長ホルモン分泌促進ペプチド
HK40087027A (en) Crf2 receptor agonists and their use in therapy
HK40087027B (en) Crf2 receptor agonists and their use in therapy
CN116514952B (zh) 一类glp-1类似物及其应用
HK40095414A (en) Crf2 receptor agonists and their use in therapy
HK40112064A (zh) Crf2受体激动剂及其在治疗中的用途
WO2024213022A1 (zh) 肠促胰素类似物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination